While vaccination against chikungunya is progressing, a worrying assessment emerges. A report by the Medicines Agency reveals serious undesirable effects linked to the IXCHIQ vaccine.
A worrying assessment
Since the start of campagne vaccinale against the chikungunya in France47 undesirable effects were reported between March and June 2025, including 18 serious.
The National Medicines Safety Agency (ANSM) has confirmed a direct link with the vaccin Ixchiq For 9 of these cases. Patients concerned are an average of 74 years. Among them, three deaths have been reported. They are all people over the age of 65 suffering from other pathologies. For a death, the accountability of the vaccine is deemed “Very likely”.
This assessment recalls the importance of reinforced monitoring, particularly in vulnerable populations, whether or not they have medical history.
Rare, but serious effects
Beyond the effects already identified, the pharmacovigilance survey has highlighted new disturbing signals. Rare but serious cases, such as encephalopathies or encephalitis, have been observed in elderly people with comorbidities. Other alerts relate to falls that occurred after vaccination and an isolated case of thrombotic microangiopathy.
These unexpected effects are now the subject of in -depth investigations at European level.
The ANSM also points to administration errors. Immunocompromised patients would have received the vaccine While it is formally contraindicated to them. These misuses underline the need for increased vigilance in the application of instructions.
Sources : Overseas the 1st, Ouest France
AllNews in France To follow on LINFO.RE
